Symrise has made a strategic equity investment in Cellibre, a US biotechnology company, to accelerate innovation in cosmetic actives.
By partnering with Cellibre, the German firm gains preferred access to proprietary, fermentation-based technology, enabling scalable production of high-value ingredients across food, beverage, cosmetics, and nutraceutical sectors.
With this investment, it said, Symrise will leverage Cellibre’s world-class biotechnology platform to enable a more resilient supply chain, mitigating seasonal and cultivation variability.
“This investment accelerates our biotechnology roadmap and strengthens our ability to deliver sustainable, high-quality solutions to our customers,” said Imke Meyer, Project Lead for Biotechnology at Symrise.
“Together with Cellibre, we will combine scientific expertise with application know-how and market reach to unlock new growth opportunities,” she added.
Cellibre brings a significant track record in designing and engineering microorganisms for the production of cultured natural products and chemicals that are utilized in pharmaceuticals, functional health, beauty ingredients, industrial applications, and more.
“Since 2017, we have been led by the belief that biology is the future of manufacturing and we are committed to creating more resilient supply chains, delivering products that are lower cost and higher quality while limiting the impact on natural ecosystems,” said Ben Chiarelli, CEO of Cellibre.
“This partnership represents another external validation of our approach, technology, and team, and will leverage the Symrise team’s global market access and deep expertise in flavours, fragrances and cosmetics — creating powerful synergies for both companies,” he added.
